Form 4: Mirum Pharmaceuticals Director Patrick J. Heron Reports Acquisition of Common Stock
SEC Form 4
Director Patrick J. Heron reports acquiring 115 shares of Mirum Pharmaceuticals common stock at $37.40 per share, while also indirectly holding significant shares through Frazier Life Sciences partnerships.
Summary
- Patrick J. Heron, a director of Mirum Pharmaceuticals, reported a transaction on September 18, 2024.
- He acquired 115 shares of common stock at a price of $37.40 per share.
- Following the transaction, Heron directly owns no shares but indirectly owns 162,308 shares through Frazier Life Sciences X, L.P. and 3,566,912 shares through Frazier Life Sciences IX, L.P.
- Heron disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides shareholders with insight into the trading activities of a company director.
Key Dates
| Date | Description |
|---|---|
| 09/18/2024 | Date of transaction: Acquisition of 115 shares of common stock. |
| 09/20/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.